Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment

The diagnosis of early and aggressive types of cancer is important for providing effective cancer therapy. Cancer-induced fibrin clots exist only within lesions. Previously, we developed a monoclonal antibody (clone 102-10) that recognizes insoluble fibrin but not fibrinogen or soluble fibrin and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Obonai, Toshifumi, Fuchigami, Hirobumi, Furuya, Fumiaki, Kozuka, Naoyuki, Yasunaga, Masahiro, Matsumura, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806360/
https://www.ncbi.nlm.nih.gov/pubmed/27009516
http://dx.doi.org/10.1038/srep23613
_version_ 1782423226169688064
author Obonai, Toshifumi
Fuchigami, Hirobumi
Furuya, Fumiaki
Kozuka, Naoyuki
Yasunaga, Masahiro
Matsumura, Yasuhiro
author_facet Obonai, Toshifumi
Fuchigami, Hirobumi
Furuya, Fumiaki
Kozuka, Naoyuki
Yasunaga, Masahiro
Matsumura, Yasuhiro
author_sort Obonai, Toshifumi
collection PubMed
description The diagnosis of early and aggressive types of cancer is important for providing effective cancer therapy. Cancer-induced fibrin clots exist only within lesions. Previously, we developed a monoclonal antibody (clone 102-10) that recognizes insoluble fibrin but not fibrinogen or soluble fibrin and confirmed that fibrin clots form continuously in various cancers. Here, we describe the development of a Fab fragment probe of clone 102-10 for tumour imaging. The distribution of 102-10 Fab was investigated in genetically engineered mice bearing pancreatic ductal adenocarcinoma (PDAC), and its effect on blood coagulation was examined. Immunohistochemical and ex vivo imaging revealed that 102-10 Fab was distributed selectively in fibrin clots in PDAC tumours 3 h after injection and that it disappeared from the body after 24 h. 102-10 Fab had no influence on blood coagulation or fibrinolysis. Tumour imaging using anti-fibrin Fab may provide a safe and effective method for the diagnosis of invasive cancers by detecting fibrin clots in tumour stroma.
format Online
Article
Text
id pubmed-4806360
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48063602016-03-25 Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment Obonai, Toshifumi Fuchigami, Hirobumi Furuya, Fumiaki Kozuka, Naoyuki Yasunaga, Masahiro Matsumura, Yasuhiro Sci Rep Article The diagnosis of early and aggressive types of cancer is important for providing effective cancer therapy. Cancer-induced fibrin clots exist only within lesions. Previously, we developed a monoclonal antibody (clone 102-10) that recognizes insoluble fibrin but not fibrinogen or soluble fibrin and confirmed that fibrin clots form continuously in various cancers. Here, we describe the development of a Fab fragment probe of clone 102-10 for tumour imaging. The distribution of 102-10 Fab was investigated in genetically engineered mice bearing pancreatic ductal adenocarcinoma (PDAC), and its effect on blood coagulation was examined. Immunohistochemical and ex vivo imaging revealed that 102-10 Fab was distributed selectively in fibrin clots in PDAC tumours 3 h after injection and that it disappeared from the body after 24 h. 102-10 Fab had no influence on blood coagulation or fibrinolysis. Tumour imaging using anti-fibrin Fab may provide a safe and effective method for the diagnosis of invasive cancers by detecting fibrin clots in tumour stroma. Nature Publishing Group 2016-03-24 /pmc/articles/PMC4806360/ /pubmed/27009516 http://dx.doi.org/10.1038/srep23613 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Obonai, Toshifumi
Fuchigami, Hirobumi
Furuya, Fumiaki
Kozuka, Naoyuki
Yasunaga, Masahiro
Matsumura, Yasuhiro
Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
title Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
title_full Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
title_fullStr Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
title_full_unstemmed Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
title_short Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
title_sort tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin fab fragment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806360/
https://www.ncbi.nlm.nih.gov/pubmed/27009516
http://dx.doi.org/10.1038/srep23613
work_keys_str_mv AT obonaitoshifumi tumourimagingbythedetectionoffibrinclotsintumourstromausinganantifibrinfabfragment
AT fuchigamihirobumi tumourimagingbythedetectionoffibrinclotsintumourstromausinganantifibrinfabfragment
AT furuyafumiaki tumourimagingbythedetectionoffibrinclotsintumourstromausinganantifibrinfabfragment
AT kozukanaoyuki tumourimagingbythedetectionoffibrinclotsintumourstromausinganantifibrinfabfragment
AT yasunagamasahiro tumourimagingbythedetectionoffibrinclotsintumourstromausinganantifibrinfabfragment
AT matsumurayasuhiro tumourimagingbythedetectionoffibrinclotsintumourstromausinganantifibrinfabfragment

Ejemplares similares